Greenwich LifeSciences Price/Book Ratio 2020-2024 | GLSI

Greenwich LifeSciences price/book ratio from 2020 to 2024. Price/book ratio can be defined as

Greenwich LifeSciences Price/Book Ratio 2020-2024 | GLSI

Greenwich LifeSciences price/book ratio from 2020 to 2024. Price/book ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$152.1B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$120.1B
Gilead Sciences (GILD)$115.4B
CSL (CSLLY)$89B
Regeneron Pharmaceuticals (REGN)$82.4B
GSK (GSK)$70.7B
Argenex SE (ARGX)$37.2B
Alnylam Pharmaceuticals (ALNY)$32.6B
BioNTech SE (BNTX)$28.4B
Biogen (BIIB)$23.4B
Illumina (ILMN)$22.9B
BeiGene (BGNE)$20.9B
Moderna (MRNA)$16.6B
Incyte (INCY)$14.4B
Genmab (GMAB)$14.2B
Insmed (INSM)$13.4B
Sarepta Therapeutics (SRPT)$12.7B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12B
Vaxcyte (PCVX)$11.8B
Exact Sciences (EXAS)$11.5B
Exelixis (EXEL)$10.4B
QIAGEN (QGEN)$9.9B
Revolution Medicines (RVMD)$9.7B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8.4B
Ascendis Pharma (ASND)$8.3B